CXCL8 and prostate carcinoma: Furthermore, we have shown that stress-induced CXCL8 signaling attenuates the sensitivity of prostate cancer cells to undergo apoptosis in response to DNA-damaging agents [9], [10], Hsp90-directed inhibitors [15], death receptor agonists (TRAIL) [11] and AR-targeted therapeutics such as bicalutimide (Casodex) [13].